No­var­tis drums up EU launch plans as CHMP gives thumbs up to Spark's gene ther­a­py Lux­tur­na

Nine months af­ter the FDA gave its land­mark OK for Spark Ther­a­peu­tics’ trail­blaz­ing gene ther­a­py Lux­tur­na, Eu­ro­pean reg­u­la­tors have sig­naled that they are ready to green­light the vi­sion loss treat­ment, too.

The team at Spark $ONCE isn’t the on­ly ones cel­e­brat­ing the pos­i­tive opin­ion from the Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use: No­var­tis, which grabbed ex-US rights to Lux­tur­na ear­li­er this year in a $170 mil­lion deal, will be com­mer­cial­iz­ing the ther­a­py once it’s ap­proved in Eu­rope.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.